Impact-First Product & Portfolio Strategy

Bringing simplicity and strategic focus to your (Gen)AI product roadmap.

Do These Strategic Gaps Sound Familiar?


"Do you get different answers on the true purpose of your (Gen)AI strategy?

Are your teams investing more energy deciding who is responsible than in driving results?"

Strategic Ambiguity


"Do you have full transparency over your portfolio?

Or, lacking a rigorous framework, is it bloating with fragmented 'prestige projects' at the expense of a synergistic, impact-first roadmap?"

Portfolio Inefficiency


"Are your (Gen)AI initiatives stalled in 'Proof-of-Concept purgatory,' while some functions are permitted to operate without measurable success metrics?"

Asymmetric ROI


"Do you still need to approve the same decision multiple times across different hierarchy levels, functions, and endless meetings?"

Organizational Drag

A Modular Approach to Impact

Our product strategy engagements are designed to create synergy by translating the complex needs of enterprise leaders into actionable roadmaps for tech innovators.

Our unique value in this translation comes from hands-on experience and a rare blend of 4 critical perspectives:

  • understanding science as a Ph.D. Scientist with neurobiological grounding,

  • the strategic foresight of a former Pharma-Life Science Strategy Consultant (EY),

  • the Senior Management execution of a former Pharma VP Digital Excellence (Daiichi Sankyo),

  • and the agility of an Entrepreneur.

This 360° view is how we bridge the gap from concept to compliant, scalable impact.

For Pharma & MedTech Leaders

Engagement 1: Portfolio Assessment (The "Problem Space")


"This standalone service is the ideal entry point. We conduct a rigorous analysis of your existing portfolio to identify inefficiencies, strategic gaps, and latent (Gen)AI value. This is our low-friction 'Proof Point' to demonstrate our 'Impact-First' approach."

Engagement 2: Impact-First Product Strategy (The "Internal Build")

"We architect your internal 'what's next.' We bring simplicity and strategic focus to your roadmap, defining clear success criteria using our VC/PE metric framework before the first sprint begins. This ensures every initiative is directly tied to measurable, sustainable impact."

For Start-up & Scale-up Founders

Engagement 1: Impact-First Product Strategy (The "Solution Space")

"We translate Pharma's 'Problem Space' for you. We align your roadmap with Pharma's actual (and often unstated) needs, compliance realities, and 'Impact' definitions, ensuring your solution achieves genuine, validated Product-Market-Fit."


Engagement 2: Pricing & Packaging (The "GTM / Sell")

"Once Product-Market-Fit is clear, we bridge the critical knowledge gap. We provide the 'insider view' on Pharma procurement, compliance, and C-level decision-making, helping you price and package your solution to accelerate enterprise adoption and shorten your sales cycle."

A Disciplined Framework Built on First Principles

Our entire advisory model is built on two non-negotiable principles:
(A) Our First Principles (The "Why") that guide our GTM, and (B) The Engagements (“The How”) that that deliver the results.

(A) Our First Principles (The "Why"):

  • Success must be defined before it can be achieved. We force clarity by starting with a measurable 'Impact' (the 'What'), deploying validated Venture Capital (VC)/Private Equity (PE) metrics (like MOIC and Burn Multiple) to define success - because "what isn't measured, isn't executed.

  • Efficiency is the ultimate competitive advantage (MOAT). We challenge every process against the 'Zero-Click' standard (the 'How') to eliminate friction for your teams and customers - whether it's streamlining Pharma procurement for a Start-up or simplifying internal workflows like Ceel.AI demonstrates for insights generation with the first real-time customer engagement platform.

(B) Our Pragmatic Process (The "How") These principles are embedded in a tangible, agile process designed for sustainable capability building:

1. The 'Portfolio Assessment' (Gateway Mandate):


We begin with this optional, standalone engagement. We conduct a rigorous analysis of your existing portfolio to identify inefficiencies (like funding fragmented 'prestige projects'), diagnose 'stalled' initiatives, and uncover hidden synergy gaps ('The Problem Space'). This delivers immediate, actionable clarity and the 'Proof Point' for our 'Impact-First' approach.

2. The 'Competitive Sprints' (Delivery & Capability Building):

This is where our approach fundamentally differs. Our agile Sprints (Sprint 1: Definition; Sprint 2: Detailing; Sprint 3: Implementation) are co-creation workshops focused on a sustainable pace that allows your teams to genuinely 'apply and learn'. We ensure knowledge is embedded, preventing the overload that causes most strategic projects to fail post-consultant departure, aiming for validated differentiators and strategic clarity on 'what to build next.

€0M+

Incremental Revenue

Co-led and launched one of Europe's first GenAI-driven call plan engagement AI/ML models, setting a new benchmark for precision engagement and operational efficiency.

Refers to 2024-25 as VP Digital Excellence at Daiichi Sankyo Europe GmbH

-0%

Time to KOL segmentation

Cut cycle time from ~2 months to < 1 minute by applying an impact-first mindset - defining sharp decision criteria and the simplest technical path to execution.

Refers to 2024-25 as VP Digital Excellence at Daiichi Sankyo Europe GmbH

€0M+

Averted Strategic Missinvestment

Rebuilt a flawed long-range forecast for a top-2 global product, leading to a fundamental, data-driven shift in the European launch strategy and improved commercial outcomes.

Refers to 2015/16 as Manager Market Insights & Business Analytics at Celgene DE

Our Proof: Measurable Impact, Not Just Decks

Your Strategic Questions, Answered

  • We reject this premise. We apply the right VC-metric to the right scenario. For internal Pharma projects, we use MOIC (Multiple on Invested Capital); for Start-up GTM, we use Burn Multiple.

    • Pharma Example (MOIC): For a (Gen)AI Content Engine, a "Big4" bespoke build might cost 500k€ per month but only delivers 150k€ in overestimated savings (a 0.3x MOIC – a massive loss). We compare this to an "Off-the-shelf" Third Party model. This might cost 200k€ but deliver 150k€ in real savings plus 150k€ in new revenue from faster content (a 1.5x MOIC). We provide you a clear, data-driven choice.

    • Start-up Example (Burn Multiple): Many MedTech Scale-up (Series A) exhbit a high Net Burn (e.g. 500k€) but low Net New ARR (e.g. 250k€), resulting in a 2.0x Burn Multiple (a "red flag" for investors). By applying our 'Zero-Click' GTM principles to their compliance and sales process, we can help them to increase their ARR to, e.g., 500k€ on the same cost base. Their new 1.0x Burn Multiple is considered "elite" (per David Sacks), making them investable.

  • This is a valid concern. Our approach directly counters the 'ROI Asymmetry' prevalent in the industry. We don't add confusion; we replace vague, legacy metrics (like 'launch trackers') with a validated framework that forces clarity from day one. It allows us to measure the success of all initiatives - innovative and established - against the same high standard: measurable impact.

  • Our 'Competitive Sprints' are not open-ended "ideation" sessions. They are a focused three-sprint process (Definition, Detailing, Implementation) governed by our 'Impact-First' and 'Zero-Click' principles. The key difference is our focus on a sustainable pace to ensure capability is truly embedded in your team, preventing the project failure that stems from consultant-driven overload.

  • A critical question. Pre-launch 'Impact' is not measured by actual revenue, but by optimizing the two levers of launch success: Forecast Integrity and Operational Efficiency.

    1. Forecast Integrity (The 'What'): This is our 'secret sauce'. Pharma forecasts often rely on vague and/or partially fitting assumptions (analogues). We challenge them by applying our proprietary adaptation of VC-metrics to your forecasted data.

    We use Physician Engagement Time-to-Impact (our compliant adaptation of CAC_Payback) to define the exact time [in months] it takes for your educational investment to generate a positive therapeutic return.

    We use Total Therapy Contribution (our adaptation of CLV_pharma) to clarify the total projected therapeutic contribution resulting from that physician's prescribing activity for eligible patients."

    2. Operational Efficiency (The 'How'): We also measure the cost of your launch preparation. We apply our metric MOIC_medical (Hours_Saved / Hours_Invested) to ensure our (Gen)AI tools and 'Zero-Click' Sprints reduce your internal overhead, generating value before Day 1 (Launch).

  • The 'Portfolio Assessment' mandate is designed to be lean and deliver value fast. A typical assessment takes 2-4 weeks, depending on complexity and your availability. The required executive time-commitment is minimal: typically a kick-off session, one mid-point check-in, and the final (actionable) readout.

Let's Architect Your 'Impact-First' Roadmap.

Our 'Selective Availability' is a commitment to mutual, on-par partnership. We seek ambitious leaders who are ready to move beyond the beaten path and share our obsession with measurable, 'Impact-First' results.

This mutual alignment allows us to provide the undivided attention required to translate ambitious visions into extraordinary outcomes. We invite you to schedule a confidential, preliminary discussion to explore our strategic fit.

Explore Strategic Fit